Literature DB >> 11172681

Inhibition of tumor cell invasiveness by chemically modified tetracyclines.

Y Gu1, H M Lee, E J Roemer, L Musacchia, L M Golub, S R Simon.   

Abstract

COLO 205 is a cell line derived from a human colon carcinoma with high degradative activity towards extracellular matrix (ECM). It has been shown that COLO 205 cells produce matrix metalloproteinases (MMPs). MMPs are a family of enzymes known to degrade components of the ECM and have been implicated in tumor invasion. In the present study, we have analyzed the multiple effects of chemically modified tetracyclines (CMTs) on the expression and activity of MMPs secreted by COLO 205 cells in vitro with the aim of evaluating these compounds for potential use in management of invasive tumors. Because COLO 205 cells can degrade an interstitial ECM in serum-free medium in vitro, we have been able to compare the effects of the tetracyclines on this measure of invasive activity with their effects on proteinase expression and activity. We demonstrate here that one of the chemically modified tetracyclines, 6-deoxy-6-demethyl-4-de(dimethylamino)tetracycline (CMT-3) can effectively inhibit ECM degradation mediated by COLO 205 cells or their conditioned medium. Gelatin zymography and immunoblots show that CMT-3 has the ability to inhibit release of MMP-2 into conditioned medium as well as to inhibit MMP-2 gelatinolytic activity, which correlates with the results from ECM degradation assays. On the basis of our findings with COLO 205 cells we have expanded our evaluation of the tetracyclines to include effects on a genetically engineered line of MDA-MB-231 breast tumor cells overexpressing MMP-9 at levels over tenfold those of the parent cell line, and on three human prostate tumor cell lines, LNCaP, DU-145, and PC-3. We show here that CMT-3 displays multiple modes of action: inhibiting MMP activity, reducing levels of MMP expression, and exhibiting selective cytotoxicity towards some of the tumor cell lines.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11172681     DOI: 10.2174/0929867013373642

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  8 in total

1.  Metalloproteinase inhibitors, nonantimicrobial chemically modified tetracyclines, and ilomastat block Bacillus anthracis lethal factor activity in viable cells.

Authors:  Salih S Kocer; Stephen G Walker; Brad Zerler; Lorne M Golub; Sanford R Simon
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

2.  Lowering the apoptotic threshold in colorectal cancer cells by targeting mitochondria.

Authors:  Kevin Sales; Jan-Willem Taanman; Sas Dijk; Marc Winslet; Jayesh Sagar
Journal:  Cancer Cell Int       Date:  2010-09-06       Impact factor: 5.722

Review 3.  Decoding and engineering tetracycline biosynthesis.

Authors:  Lauren B Pickens; Yi Tang
Journal:  Metab Eng       Date:  2008-10-22       Impact factor: 9.783

4.  Phase II study of interferon-alpha and doxycycline for advanced renal cell carcinoma.

Authors:  Michael Huie; Kurt Oettel; Lynn Van Ummersen; Kyung Mann Kim; Yulin Zhang; Mary Jane Staab; Dottie Horvath; Rebecca Marnocha; Jeff Douglas; Amy Drezen; Dona Alberti; George Wilding
Journal:  Invest New Drugs       Date:  2006-05       Impact factor: 3.651

5.  A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas.

Authors:  Quincy S C Chu; Bahram Forouzesh; Samira Syed; Monica Mita; Garry Schwartz; Joshua Cooper; Joshua Copper; Janet Curtright; Eric K Rowinsky
Journal:  Invest New Drugs       Date:  2007-01-20       Impact factor: 3.651

6.  Does doxycycline work in synergy with cisplatin and oxaliplatin in colorectal cancer?

Authors:  Jayesh Sagar; Kevin Sales; Sas Dijk; JanWillem Taanman; Alexander Seifalian; Mark Winslet
Journal:  World J Surg Oncol       Date:  2009-01-06       Impact factor: 2.754

Review 7.  The Impact of Human Papilloma Viruses, Matrix Metallo-Proteinases and HIV Protease Inhibitors on the Onset and Progression of Uterine Cervix Epithelial Tumors: A Review of Preclinical and Clinical Studies.

Authors:  Giovanni Barillari; Paolo Monini; Cecilia Sgadari; Barbara Ensoli
Journal:  Int J Mol Sci       Date:  2018-05-09       Impact factor: 5.923

8.  CtcS, a MarR family regulator, regulates chlortetracycline biosynthesis.

Authors:  Lingxin Kong; Jia Liu; Xiaoqing Zheng; Zixin Deng; Delin You
Journal:  BMC Microbiol       Date:  2019-12-10       Impact factor: 3.605

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.